Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Nov 20, 2023
Date Accepted: Dec 29, 2023

The final, peer-reviewed published version of this preprint can be found here:

Authors’ Reply: “The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies”

Wang L, Liu S, Jiang S, Li C, Lu L, Fang Y, Li S

Authors’ Reply: “The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies”

JMIR Public Health Surveill 2024;10:e54756

DOI: 10.2196/54756

PMID: 38478903

PMCID: 10973956

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Reply to “Comment on ‘Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients with Hemophilia A in China: Discrete Choice Experiment Study’ ”from Li et al.

  • Limin Wang; 
  • Shimeng Liu; 
  • Shan Jiang; 
  • Chaofan Li; 
  • Liyong Lu; 
  • Yunhai Fang; 
  • Shunping Li

International Registered Report:

RR2-10.2196/45747


 Citation

Please cite as:

Wang L, Liu S, Jiang S, Li C, Lu L, Fang Y, Li S

Authors’ Reply: “The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies”

JMIR Public Health Surveill 2024;10:e54756

DOI: 10.2196/54756

PMID: 38478903

PMCID: 10973956

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.